175 reports of this reaction
5.0% of all ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE reports
#1 most reported adverse reaction
COVID 19 is the #1 most commonly reported adverse reaction for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE, manufactured by The Procter & Gamble Manufacturing Company. There are 175 FDA adverse event reports linking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE to COVID 19. This represents approximately 5.0% of all 3,480 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COVID 19 is moderately reported among ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE users, representing a notable but not dominant share of adverse events.
In addition to covid 19, the following adverse reactions have been reported for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE:
The following drugs have also been linked to covid 19 in FDA adverse event reports:
COVID 19 has been reported as an adverse event in 175 FDA reports for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COVID 19 accounts for approximately 5.0% of all adverse event reports for ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE, making it one of the most commonly reported side effect.
If you experience covid 19 while taking ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, AND DOXYLAMINE SUCCINATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.